Good response to tolvaptan shortens hospitalization in patients with congestive heart failure
| Autor: | Tomohito Kogure, Kazuyuki Hamada, Nobuhisa Hagiwara, Kentaro Jujo, Katsumi Saito |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Tolvaptan Administration Oral 030204 cardiovascular system & hematology Plasma renin activity law.invention 03 medical and health sciences 0302 clinical medicine law Aquaretic Internal medicine medicine Humans 030212 general & internal medicine Blood urea nitrogen Aged Retrospective Studies Heart Failure business.industry Standard treatment Benzazepines medicine.disease Intensive care unit Endocrinology Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business Antidiuretic Hormone Receptor Antagonists medicine.drug Fluid balance |
| Zdroj: | Heart and vessels. 33(4) |
| ISSN: | 1615-2573 |
| Popis: | Tolvaptan has been gradually spread to use as a potent diuretic for congestive heart failure in the limited country. However, the response to this aquaretic drug still is unpredictable. A total of 92 patients urgently hospitalized due to congestive heart failure and treated with tolvaptan in addition to standard treatment was retrospectively analyzed. Responder of tolvaptan treatment was defined as a patient with peak negative fluid balance greater than 500 mL/day, and clinical profiles were compared between 76 responders and 16 non-responders. Responders started to increase daily urine volume (UV) from Day 1 through Day 3. In contrast, non-responders showed no significant increase in daily UV from the baseline up to Day 5. Time between admission and tolvaptan administration was shorter in responders, even without statistical significance (3.3 vs. 4.6 days, p = 0.053). Multivariate analysis revealed that blood urea nitrogen (BUN) [cutoff: 34 mg/dL, odds ratio (OR) 9.0, 95% confidence interval (CI) 1.42–57.3, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink